Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 5/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 3/20 | 0.39 |
| ▸ | RXRA | P19793 | 2/20 | 0.39 |
| ▸ | RXRB | P28702 | 2/20 | 0.39 |
| ▸ | RXRG | P48443 | 2/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8282581 | 0.92 | PTGER1 (0.40) | PTGER1CYP2C9GLSSMN1; SMN2BRD4 | |
| SCHEMBL2953087 | 0.92 | GAA (0.41) | PTGER1CYP2C9GLSSMN1; SMN2BRD4 | |
| SCHEMBL8283417 | 0.89 | PTGER1 (0.38) | PTGER1CYP2C9GLSSMN1; SMN2BRD4 | |
| SCHEMBL12462645 | 0.85 | PTPN1 (0.42) | PTGER1CYP2C9GLSSMN1; SMN2BRD4 | |
| SCHEMBL2946340 | 0.83 | PTPN1 (0.45) | LCK | |
| SCHEMBL1715609 | 0.81 | ADORA2A (0.49) | PTGER1CYP2C9SMN1; SMN2BRD4LCK | |
| SCHEMBL5767787 | 0.81 | CSNK2A2 (0.53) | PTGER1CYP2C9GLSBRD4PTGER4 | |
| SCHEMBL13398657 | 0.79 | LCK (0.48) | CYP2C9SMN1; SMN2LCKPI4KB | |
| SCHEMBL1716047 | 0.76 | PTGER1 (0.49) | PTGER1SMN1; SMN2BRD4RXRARXRB | |
| SCHEMBL14705866 | 0.74 | ALDH1A1 (0.47) | LCKPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709018-B1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI AVENTIS (FR) | 2011-07-20 | — | — | EP | disclosed |
| EP-1709018-B1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI AVENTIS (FR) | 2011-07-20 | — | — | EP | disclosed |
| US-7759377-B2 | Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors | SANOFI-AVENTIS (FR) | 2010-07-20 | — | — | US | disclosed |
| US-7759377-B2 | Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors | SANOFI-AVENTIS (FR) | 2010-07-20 | — | — | US | disclosed |
| US-7759377-B2 | Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors | SANOFI-AVENTIS (FR) | 2010-07-20 | — | — | US | disclosed |
| US-20080176911-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| US-20080176911-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| US-20080176911-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| US-7371770-B2 | Acylaminothiazole derivatives and use thereof as β-amyloid inhibitors | SANOFIAVENTIS (FR) | 2008-05-13 | — | — | US | disclosed |
| US-7371770-B2 | Acylaminothiazole derivatives and use thereof as β-amyloid inhibitors | SANOFIAVENTIS (FR) | 2008-05-13 | — | — | US | disclosed |
| US-7371770-B2 | Acylaminothiazole derivatives and use thereof as β-amyloid inhibitors | SANOFIAVENTIS (FR) | 2008-05-13 | — | — | US | disclosed |
| US-20060293366-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI-AVENTIS (FR) | 2006-12-28 | — | — | US | disclosed |
| EP-1709018-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | Sanofi-Aventis (FR) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073202-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005073202-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176911-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | APP, BACE1, ATG4A | PTGER1 1730/4885CYP2C9 4724/4885GLS 1429/4885 |
| US-20060293366-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | APP, BACE1, ATG4A | PTGER1 1730/4885CYP2C9 4724/4885GLS 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.